12.18 2024

AP Biosciences Receives Approval from Australia HRECs for Phase 1 Clinical Trial of AP402

AP402 has received approval and CTN clearance from the HREC and TGA in Australia to initiate Phase 1/2 clinical trials.

11.21 2024

Six bispecific antibody companies you should know about

AP Biosciences has been recognized by the European media Labiotech as one of the world's top six emerging companies in bispecific antibody development, highlighting its advanced antibody engineering capabilities and market influence.

10.21 2024

APBio Partner, Innovent Biologics, Shares Positive Clinical Data for IBI302 at AAO 2024

Innovent Biologics, presented encouraging Phase 2 clinical results for IBI302—a dual-targeted anti-VEGF/complement therapy for nAMD.

09.18 2024

Two targets, one solution: The rise of bispecific antibodies

Bispecific antibodies are currently receiving significant attention in the biopharma industry, and it is expected that more bispecific antibodies will be approved in the future.

09.04 2024

Nikkei News Repost: Taiwan's Growing Bioindustry

AP Biosciences, founded in 2013 in Taiwan, specializes in bispecific antibody drug development. Led by Dr. Jeng Her, who previously co-founded KaloBios Pharmaceuticals in the U.S.. Encouraged by Taiwan's policies, Dr. Her returned to establish AP Biosciences after successfully taking his U.S. company public.

06.01 2024

AP Biosciences Inc completed its Series D financing with 38 million USD raised in June 2024

AP Biosciences Inc completed its Series D financing with 38 million USD raised in June 2024